Effects of Subchronic Treatment With Selegiline on <sc>L</sc>-DOPA-Induced Increase in Extracellular Dopamine Level in Rat Striatum

概要

論文の詳細を見る
Selegiline is used an adjunct to <sc>L</sc>-DOPA therapy. We investigated extracellular striatal dopamine (DA) level in awake rats treated with <sc>L</sc>-DOPA and/or selegiline using a microdialysis method. Rats given 10 mg/kg, i.p. per day selegiline for 7 days were administered with a single dose of 100 mg/kg, i.p. <sc>L</sc>-DOPA 0 (3 h), 1, 3, 7, 14, 21, or 28 days after the last selegiline treatment. Carbidopa was administered 0.5 h before <sc>L</sc>-DOPA administration. The significant increase in basal DA level before <sc>L</sc>-DOPA treatment persisted until 1 day after the last selegiline treatment, and the significant decrease in basal DOPAC level persisted for more than 28 days. Thus, selegiline affected DA catabolism for more than 28 days. Total monoamine oxidase (MAO) and MAO-B activities at day 0 decreased by 22% and 5.7%, respectively. The significant enhancement of <sc>L</sc>-DOPA-induced increase in DA level was observed until 3 days after the last selegiline treatment. Next, the effects of reducing <sc>L</sc>-DOPA dose by 25% were examined 3 h after the last selegiline treatment. A dose-dependent decrease in DA level was observed, indicating that DA level in selegiline-treated rats can be controlled by <sc>L</sc>-DOPA dose.
公益社団法人日本薬理学会の論文